
    
      Phase II, open, not randomized clinical trial, to evaluate the sequential Taxotere速, followed
      by Myocet速 and Cyclophosphamide first line treatment in her2 negative breast cancer patients.

      The purpose of this study is to determine how many pathological complete responses are
      achieved in patients treated with taxotere速 (T) followed by Myocet速 (M)and Cyclophosphamide
      (MC) first line treatment in HER2 negative brest cancer patients.
    
  